Copyright:

All rights reserved.

This information may be freely used and copied for educational and other non-commercial purposes, provided that any reproduction of data be accompanied by an acknowledgement of EBOVAC2 as the source (© EBOVAC2). This does not apply to the pages and images with explicitly reserved reproduction right : © followed by the right owner and the year of first circulation. Reproduction of the latter requires prior authorization from EBOVBAC2 for the pages.

Privacy Policy :

Inserm Transfert will not to reveal information obtained from users. Such information is confidential and will only be used with users consent.

According to the Law n°78-17 "Informatique et Libertés/software and freedoms" and its amendments, users have the right to access, modify, correct and delete any personal data collected when visiting the site. The users can exercise such rights with:

INSERM TRANSFERT
7 rue de Watt
75013 Paris, FRANCE
©2015 EBOVAC2
Design & Programming: ML Com, France

News

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018 Registration - Enregistrement

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research